< >

HyperAcute Immunotherapy

NewLink Genetics has multiple HyperAcute immunotherapies currently under development in a variety of tumors

Phase 3 Trial in Pancreatic Cancer

Now enrolling patients with borderline resectable or locally advanced unresectable pancreatic cancer

Phase 2b/3 Trial in Lung Cancer

Now enrolling patients with progressive or relapsed non-small cell lung cancer (NSCLC)

Investor Relations

Keep up with the latest news and presentations
Vaccine Candidate Potentially Effective Against Ebola in Large Trial in Guinea
July 31, 2015

NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015

ANNOUNCEMENTS